Back

Therapeutic effects of phosphodiesterase 5 inhibitors in patients with heart failure with preserved ejection fraction (HFpEF) and combined post- and pre-capillary pulmonary hypertension (Cpc-PH).

27 August 2017 (14:00 - 18:00)
Organised by:
Congress Presentation Part of: Poster session 3 - Pulmonary hypertension: pathophysiology Chronic pulmonary hypertension ESC Premium Access ESC Congress 2017

About the speaker

Photo
Doctor Tilmann Kramer

Cologne University Hospital - Heart Center, Cologne (Germany)

9 More presentations in this session

Presentation thumbnail
Doctor J. Latal (Olomouc, CZ)
Abstract Slides
Presentation thumbnail
Professor K. Schaefer (Mainz, DE)
Abstract
Presentation thumbnail
Associate Professor S. Caravita (Bergamo, IT)
Abstract
Presentation thumbnail
Doctor O. Raitiere (Le Havre Cedex, FR)
Abstract
Presentation thumbnail
Doctor K. Chung (PERTH, AU)
Abstract Slides

Access the full session

Session thumbnail
Poster session 3 - Pulmonary hypertension: pathophysiology

The Event

Event poster

ESC Congress 2017

27 August 2017 14:00 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources